VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Clinical trial NCT00116844 · COMPLETED
Trial details
- NCT number
- NCT00116844
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2005-03-29
- Primary completion
- 2006-01-10
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.